Oncotarget, a leading scientific journal, was the sponsor of the Gordon Research Conference. The convention aimed at highlighting latest research on functions of matrix metalloproteinases (MMPS) and how endogenous mechanisms control behavior of MMPS. Discussions centered on opportunities for new research and how the studies could guide scientists in the designing of metalloproteinase-targeted modulators to treat human diseases.
When the Research Began
Since scientists discovered matrix metalloproteinases (MMPs), ADAM and ADAMTS as tissue remodeling enzymes more than 50 years ago, they have identified them as factors that contribute to diseases such as cancer, neurodegeneration, and inflammatory diseases. After the discovery, scientists marked them as a drug target since they are both good and bad actors.
Early clinical trials
Early clinical trials of use of metalloproteinases as inhibitors were unsuccessful for several reasons. First, not all scientists appreciated functions of individual metalloproteinases. Notably, while some metalloproteinases contribute to diseases, recent research has shown that several others prevent diseases, facilitate regeneration, reduce inflammation, and support several beneficial functions. Thus, scientists aim to discover particular functions of individual MMPs and understand how the activities are controlled. This will allow them to identify specific harmful function that can be treated with new therapies.
Oncology is a scientific journal whose mission is to rapidly and widely spread scientific results. The publication also aims at maximizing impact of scientific studies via meaningful review and eliminating barriers between specialties. The journal accepts publications on several related fields such as endocrinology, neuroscience, ageing, and cell biology. This has resulted into meaningful collaborations between scientists who specialize in different areas.
Oncotarget, which was founded in 2010, is released every week. It is a highly ranked medical journal that is indexed in PubMed, Index Medicus, and Scopus. The publication is released online and can be easily accessed by everyone globally. The editors-in-chief of Oncotarget are Andrei Gudkov and Mikhail Blagosklonny. Blagosklonny is a professor in Oncology at Roswell Park Institute and has published in more than 200 papers in scientific journals. Gudkov is also a professor and a medical research vice president at Roswell Park Institute. Visit Oncotarget’s profile page at facebook.com